Baseline characteristics in the Hypertension Prevention Trial

K. M. Brown, A. Oberman, M. L. Van Natta, J. L. Forster

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Scopus citations


The Hypertension Prevention Trial (HPT) was a randomized, controlled, multicenter (four clinics, four resource centers) trial designed to test the feasibility of achieving and sustaining dietary changes in the intake of calories, sodium, and potassium and to assess the effect of those changes on blood pressure in a normotensive population. The trial involved 841 men and women (plus a test cohort of 78) who, at the first baseline (BL) examination were in the age range of 25-49 years and had diastolic blood pressure (DBP) ≥76 but <100 mm Hg (average of two readings), and at the examination prior to randomization (BL 2), had DBP ≥78 but <90 mm Hg (also averaged). Participants were randomly assigned to a control treatment group (no dietary counseling) or to one of four dietary treatment groups involving counseling designed to reduce calorie intake, reduce sodium intake, reduce sodium and calorie intake, and reduce sodium and increase potassium intake. This chapter presents HPT baseline characteristics by weight stratum, clinic, and treatment group for various demographic, medical history, and nutritional characteristics, for several physiologic variables used in monitoring treatment compliance, and for blood pressure. The degree of comparability observed among treatment groups was within the range expected for the randomization procedure used.

Original languageEnglish (US)
Title of host publicationControlled Clinical Trials
Edition3 SUPPL.
StatePublished - 1989
Externally publishedYes


  • Baseline characteristics
  • Baseline results
  • Behavior modification
  • Blood pressure
  • Clinical trial
  • Data collection
  • Demographic characteristics
  • Dietary trial
  • Hypertension
  • Hypertension trial
  • Intervention trial
  • Primary prevention trial


Dive into the research topics of 'Baseline characteristics in the Hypertension Prevention Trial'. Together they form a unique fingerprint.

Cite this